Self-Stabilizing Biopolymer Radionuclide Delivery for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pancreatic cancer, including external beam radiotherapy and brachytherapy, are ineffective due to the tumor's aggressive phenotype, dense desmoplastic stroma, and anatomical challenges, leading to limited drug delivery and significant side effects, resulting in poor clinical outcomes and low survival rates.
Innovation Solution
Development of self-assembling conjugates comprising radionuclides coupled to elastin-like polypeptides that form intratumoral deposits for targeted radiation therapy combined with systemic or local chemotherapy to overcome tumor resistance and improve treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If external beam radiotherapy is used to treat pancreatic cancer, then the treatment can be administered to patients with locally advanced tumors, but the radiation dose must be limited to avoid serious side effects in adjacent healthy tissue such as the duodenum and stomach
Solution Approach 1:
The patent applies local quality by converting the radiation delivery system from external beam to internal brachytherapy, where radioactive seeds are implanted directly into the tumor. This creates a localized high-dose radiation field within the tumor while the dose falls off rapidly with distance, protecting adjacent healthy tissues such as the duodenum and stomach from significant radiation exposure
Solution Approach 2:
The patent uses biodegradable polymer matrices as an intermediary carrier system that delivers radionuclides directly to the tumor site. This intermediary system enables controlled local delivery of radiation and chemotherapy agents, maintaining high concentrations at the tumor while minimizing exposure to surrounding healthy tissues
2Reliability
If higher radiation dose fractions are administered to overcome tumor resistance, then local tumor control may be improved, but grade 3 toxicities such as bleeding and bowel perforation increase significantly
Solution Approach 1:
The brachytherapy approach creates a highly localized radiation dose distribution where the tumor receives high doses for effective control while adjacent structures receive progressively lower doses. This spatial differentiation of dose quality allows aggressive tumor treatment without proportionally increasing systemic toxicities
Solution Approach 2:
The patent employs preoperative or neoadjuvant brachytherapy to shrink the tumor and reduce its resistance before definitive treatment. This preliminary high-dose localized radiation therapy sensitizes the tumor to subsequent treatments while maintaining acceptable toxicity profiles through precise local delivery
3Ease of operation
If conventional brachytherapy with temporary catheters or permanent low-dose seeds is used, then the radioactive source is placed inside the tumor, but clinical outcomes for pancreatic cancer are not improved
Solution Approach 1:
The patent uses composite biodegradable polymer matrices that combine multiple therapeutic modalities - radionuclide delivery, chemotherapy agent delivery, and potential gene therapy components - into a single integrated system. This composite approach overcomes the limitations of conventional single-modality brachytherapy by providing synergistic multi-component treatment
Solution Approach 2:
The patent fundamentally changes the dose delivery parameters by using high-dose-rate brachytherapy with carefully selected radionuclides (such as I-125, Pd-103, or Cs-131) that provide optimal balance between tumor control and normal tissue protection. The biodegradable matrix also enables controlled release kinetics that maintain therapeutic concentrations over extended periods
4Stability of the object's composition
If the dense desmoplastic stroma is present in pancreatic tumors, then the tumor microenvironment is formed, but transport barriers are created that inhibit drug delivery
Solution Approach 1:
The biodegradable polymer matrix acts as an intermediary delivery system that penetrates and distributes therapeutic agents through the dense desmoplastic stroma. The matrix material facilitates controlled diffusion of drugs and radionuclides through the extracellular matrix, overcoming the transport barriers created by the stromal architecture
Solution Approach 2:
The patent replaces mechanical injection-based drug delivery with a diffusion-based release system. The biodegradable matrix provides sustained release of therapeutic agents through controlled diffusion, eliminating the need for high-pressure injection that would be required to force drugs through the dense stromal barriers
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy achieves significant tumor regression, improved survival rates, and reduced side effects by delivering therapeutic agents directly to the tumor site, enhancing the effectiveness of radiation therapy and chemotherapy.
Implementation Method 1
heating the composition to a body temperature to induce a phase transition of the elastin-like polypeptide from a soluble state to an insoluble state
Implementation Method 2
at least one radionuclide coupled to a first elastin-like polypeptide... delivering radionuclide brachytherapy... expose the tumor to ionizing radiation
Data Source
AI summary
Described herein are compositions for liquidly injectable, self-stabilizing biopolymers for the delivery of radionuclide brachytherapy. Also described herein are methods of using the compositions.